Sally Mokhtari

发表

Large-scale manufacturing and characterization of CMV-CD19CAR T cells

Xiuli Wang, J. Zaia, S. Forman, 2022, Journal for ImmunoTherapy of Cancer.

Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant.

G. Marcucci, I. Aldoss, S. Forman, 2021, Blood advances.

Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage-Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.

G. Marcucci, I. Aldoss, S. Forman, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies.

G. Marcucci, I. Aldoss, S. Forman, 2021, Transplantation and cellular therapy.

Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations.

D. Weisenburger, G. Marcucci, I. Aldoss, 2019, Clinical lymphoma, myeloma & leukemia.

Protective Effect of HLA-DPB1 Mismatch Remains Valid in Reduced-Intensity Conditioning Unrelated Donor Hematopoietic Cell Transplantation

A. Nademanee, S. Forman, D. Snyder, 2019, Bone Marrow Transplantation.

SARS-CoV-2 infection in patients with β-thalassemia : Experience from Lebanon

G. Marcucci, V. Pullarkat, H. Ali, 2021 .

Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study

G. Marcucci, S. Forman, S. Rahmanuddin, 2021, Blood advances.

MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.

Lixin Yang, G. Marcucci, I. Aldoss, 2019, Blood advances.

Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivation.

G. Marcucci, J. Zaia, S. Forman, 2019, Leukemia research.

Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis.

A. Nademanee, S. Forman, A. Salhotra, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia

G. Marcucci, I. Aldoss, P. Curtin, 2021, Cancer.

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia

I. Aldoss, S. Forman, D. Snyder, 2022 .

Long-term Outcomes of Allogeneic Hematopoietic Cell transplantation with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as GVHD prophylaxis in Patients with Acute Lymphoblastic Leukemia.

G. Marcucci, I. Aldoss, S. Forman, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide

J. Wong, G. Marcucci, I. Aldoss, 2022, Blood advances.

Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease.

K. Huelsman, S. Forman, R. Spielberger, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Long-term follow-up of patients with poor-risk acute leukemia treated on a phase 2 trial undergoing intensified conditioning regimen prior to allogeneic hematopoietic cell transplantation

Jeffery Y C Wong, G. Marcucci, I. Aldoss, 2021, Leukemia & lymphoma.

Long term outcomes of patients with Acute Myeloid Leukemia treated with myeloablative FTBI based conditioning with Tacrolimus and sirolimus based GVHD prophylaxis regimen: 6 year follow up from Single Center.

G. Marcucci, I. Aldoss, S. Forman, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL

G. Marcucci, I. Aldoss, P. Curtin, 2022, Blood advances.

Refractory primary autoimmune myelofibrosis treated with ruxolitinib

G. Marcucci, V. Pullarkat, H. Ali, 2021, American journal of hematology.

Long-term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation From Unrelated Donor Using Tacrolimus/Sirolimus-based GvHD Prophylaxis: Impact of HLA Mismatch

A. Nademanee, S. Forman, D. Snyder, 2020, Transplantation.

Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation.

A. Ganser, M. Labopin, A. Nagler, 2020, Blood advances.

Cytokine gene polymorphisms are associated with response to blinatumomab in B‐cell acute lymphoblastic leukemia

Xiwei Wu, G. Marcucci, Wei Chen, 2021, European journal of haematology.

Clinical and immunologic responses to extracorporeal photopheresis and low-dose IL-2 in patients with steroid refractory chronic graft-versus host disease

Xiwei Wu, I. Aldoss, A. Salhotra, 2022, Bone Marrow Transplantation.

Cost analysis of ganciclovir and foscarnet in recipients of allogeneic hematopoietic cell transplant with cytomegalovirus viremia

J. Zaia, J. Ito, J. Kriengkauykiat, 2019, Transplant infectious disease : an official journal of the Transplantation Society.

Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

A. Nademanee, G. Marcucci, S. Forman, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Phase II Trial of Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation

A. Nademanee, G. Marcucci, I. Aldoss, 2020 .

Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes

Lixin Yang, G. Marcucci, I. Aldoss, 2021, Blood Cancer Journal.

Iron Overload is Associated with Delayed Engraftment and Increased Non-Relapse Mortality in Recipients of Umbilical Cord Blood Hematopoietic Cell Transplantation.

A. Nademanee, G. Marcucci, I. Aldoss, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Ph-like acute lymphoblastic leukemia in adults: understanding pathogenesis, improving outcomes, and future directions for therapy

I. Aldoss, V. Pullarkat, M. Afkhami, 2023, Leukemia & lymphoma.

High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia‐like fusions

G. Marcucci, I. Aldoss, P. Curtin, 2023, American journal of hematology.

Incidence and Risk Factors of CMV Reactivation after Haploidentical Hematopoietic Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide - Possible Role of Donor KIR Genotypes

A. Nademanee, G. Marcucci, I. Aldoss, 2018, Blood.

Tocilizumab for Cytokine Release Syndrome Management after Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis.

G. Marcucci, I. Aldoss, P. Curtin, 2023, Transplantation and cellular therapy.

Association of pre-transplant vancomycin resistant enterococcus colonization status on long-term outcomes of allogeneic-hematopoietic cell transplantation

S. Forman, A. Artz, R. Spielberger, 2022, Bone Marrow Transplantation.

Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations

G. Marcucci, I. Aldoss, S. Forman, 2022, Blood.